Intraosseous Antibiotics for Osseointegration (IOAOI)
The purpose of this research study is to learn about the characteristics of infection in osseointegration patients. This research study will also study how safe and effective it is to use antibiotics inside the bone.
調査の概要
詳細な説明
The goal of this multi-center prospective trial is to assess the characteristics of infection among patients with osseointegrated prosthesis and the safety and effectiveness of intraosseous antibiotic delivery.
Participants will enroll in an observational arm. Participants who require surgery for infection may enroll in an interventional arm assessing the safety and feasibility of intraosseous antibiotic administration as a potential treatment for infection.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Christine Churchill, MA
- 電話番号:704-355-6947
- メール:Christine.Churchill@advocatehealth.org
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Anschutz Medical Campus
-
コンタクト:
- Mohamed Awad, MD
- 電話番号:706-832-9969
- メール:mohamed.awad@cuanschutz.edu
-
主任研究者:
- Danielle Melton, MD
-
-
New York
-
New York、New York、アメリカ、10021
- Hospital for Special Surgery
-
コンタクト:
- Lediona Ardolli
- 電話番号:646-714-6362
- メール:ardollil@hss.edu
-
主任研究者:
- S. Robert Rozbruch, MD
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- Atrium Health Carolinas Medical Center
-
主任研究者:
- Joseph R Hsu, MD
-
コンタクト:
- Rachel B Seymour, PhD
- 電話番号:704-441-5365
- メール:Rachel.Seymour@advocatehealth.org
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Perelman School of Medicine
-
主任研究者:
- Benjamin Potter, MD
-
コンタクト:
- Annamarie Horan, PhD
- 電話番号:215-847-0132
- メール:horana@pennmedicine.upenn.edu
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- UT Health San Antonio
-
コンタクト:
- Nick Lucio, BA
- 電話番号:210-567-5142
- メール:luciond@uthscsa.edu
-
主任研究者:
- Joseph Alderete, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Treated with osseointegration for transfemoral, transhumeral, or transtibial amputation and presenting with concern for surgical site infection
- >18 years of age
Exclusion Criteria:
- Unable to follow up at site for 1 year
- Patients that speak neither English nor Spanish
- <18 years of age
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Observational
Patients that do not require surgery for infection |
|
|
実験的:Intraosseous Antibiotics for Osseointegration
Patients that require surgery for infection |
After debridement, patients will receive intraosseous (IO) vancomycin 500mg in 150ml of normal saline during surgery. The solution will be prepared by the hospital pharmacy and administered via an IO cannula. The cannula will be placed proximal to the intramedullary fixture. In cases where a tourniquet can be utilized proximal to the IO cannula, the antibiotic is delivered as a bolus. Tourniquet must be up for 1 hour after installation of the IO cases where the residual limb is too short to allow tourniquet (pneumatic or elastic) proximal to the IO cannula, the intraosseous antibiotic must be infused at a rate not to exceed 10mg/min or less. This can be accomplished by connecting intravenous tubing to the antibiotic mixture and the IO cannula. In cases without a tourniquet, IO infusion should begin during the irrigation phase and continue through the complete closure of the wound, since it requires a significant amount of time 50-60 min. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Patients Who Develop Wound Dehiscence
時間枠:Week 2
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 2
|
|
Number of Patients Who Develop Wound Dehiscence
時間枠:Week 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 6
|
|
Number of Patients Who Develop Wound Dehiscence
時間枠:Month 3
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 3
|
|
Number of Patients Who Develop Wound Dehiscence
時間枠:Month 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 6
|
|
Number of Patients Who Develop Wound Dehiscence
時間枠:Month 12
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 12
|
|
Number of Patients Who Develop Superficial Infection
時間枠:Week 2
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 2
|
|
Number of Patients Who Develop Superficial Infection
時間枠:Week 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 6
|
|
Number of Patients Who Develop Superficial Infection
時間枠:Month 3
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 3
|
|
Number of Patients Who Develop Superficial Infection
時間枠:Month 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 6
|
|
Number of Patients Who Develop Superficial Infection
時間枠:Month 12
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 12
|
|
Number of Patients Who Develop Deep Surgical Site Infection
時間枠:Week 2
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 2
|
|
Number of Patients Who Develop Deep Surgical Site Infection
時間枠:Week 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
時間枠:Month 3
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 3
|
|
Number of Patients Who Develop Deep Surgical Site Infection
時間枠:Month 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
時間枠:Month 12
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 12
|
|
Number of Patients With Treatment Failure
時間枠:Week 2
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 2
|
|
Number of Patients With Treatment Failure
時間枠:Week 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 6
|
|
Number of Patients With Treatment Failure
時間枠:Month 3
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 3
|
|
Number of Patients With Treatment Failure
時間枠:Month 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 6
|
|
Number of Patients With Treatment Failure
時間枠:Month 12
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 12
|
|
Rate of Adverse Events
時間枠:Week 2
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 2
|
|
Rate of Adverse Events
時間枠:Week 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 6
|
|
Rate of Adverse Events
時間枠:Month 3
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 3
|
|
Rate of Adverse Events
時間枠:Month 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 6
|
|
Rate of Adverse Events
時間枠:Month 12
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 12
|
|
Rate of antibiotic-complications
時間枠:Week 2
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 2
|
|
Rate of antibiotic-complications
時間枠:Week 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 6
|
|
Rate of antibiotic-complications
時間枠:Month 3
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 3
|
|
Rate of antibiotic-complications
時間枠:Month 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 6
|
|
Rate of antibiotic-complications
時間枠:Month 12
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS -29)
時間枠:2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The PROMIS-29 is a free to use, publicly available generic health related quality of life measure that includes seven domains: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. A 5-point Likert scale is used for each question and norm-based total scores (range 0-100) have been calculated so that 50 represents the mean and one standard deviation is 10 points. Higher scores represent better function. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans RAND 12 (VR-12) Health Survey - Physical Component Score
時間枠:2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Physical Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans Rand 12 (VR12) Health Survey - Mental Component Score
時間枠:2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Mental Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Numeric Rating Scale
時間枠:2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
A scale from 0-10, where 0 is no pain and 10 is the worst pain. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Brief Pain Inventory (BPI)
時間枠:2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The BPI is a commonly used, validated 15-item measure of pain intensity and interference with daily life. There is a pain severity score and a pain interference score. Both are 0-10, with 0 being no pain and 10 being worst pain imaginable (for pain severity) and 0 being does not interfere and 10 being completely interfered (for pain interference). Lower scores are better. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
協力者と研究者
捜査官
- 主任研究者:Joseph R Hsu, MD、Wake Forest University Health Sciences
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IRB00147620
- 40010222 (その他の識別子:Department of Defense)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。